Evanston, Illinois, United States Magnetar Capital appeared to be the VC, which was created in 2005. The company was established in North America in United States. The main department of described VC is located in the Evanston.
Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Magnetar Capital works on 4 percentage points less the average amount of lead investments. The increased amount of exits for fund were in 2003. The real fund results show that this VC is 5 percentage points more often commits exit comparing to other companies.
Besides them, we counted 2 critical employees of this fund in our database.
The fund has no exact preference in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Medical Device, Life Science. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight SurgRx, Inc, Fountainhead Commercial Capital, Kintera.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Magnetar Capital, startups are often financed by Wells Fargo Securities, California Technology Ventures, Cadence Bancorp. The meaningful sponsors for the fund in investment in the same round are Wanxiang Healthcare Investments, WS Investments, Trellis Health Ventures. In the next rounds fund is usually obtained by Prospect Venture Partners, New Enterprise Associates, Alta Partners.
Related Funds
| Fund Name | Location |
| Aurora Capital Partners | California, Los Angeles, United States |
| Boyaruide | Beijing, China, Haidian |
| Kashiwabara | Japan, Minato |
| Learning Technologies Group | Brighton, East Sussex, United Kingdom |
| LG Venture Investment | Seoul, Seoul-t'ukpyolsi, South Korea |
| MedTech Venture Partners | California, San Francisco, United States |
| Rein Capital | Lakewood, New Jersey, United States |
| SL Ventures | New Jersey, United States, Wyckoff |
| Weta Digital | New Zealand, Wellington, Wellington |
| Where Angels Fund | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
CoreWeave | $200M | 31 May 2023 | New York, New York, United States | ||
CoreWeave | $221M | 20 Apr 2023 | New York, New York, United States | ||
Enable Injections | $215M | 27 Jan 2022 | Cincinnati, Ohio, United States | ||
ViRB | $3M | 02 Jan 2022 | Brookline, Massachusetts, United States | ||
Activ Surgical | $45M | 02 Jul 2021 | Boston, Massachusetts, United States | ||
OncoResponse | $40M | 31 Mar 2021 | Seattle, Washington, United States | ||
Imvax | $112M | 16 Jul 2020 | Philadelphia, Pennsylvania, United States | ||
Imvax | $40M | 10 Sep 2019 | Philadelphia, Pennsylvania, United States | ||
Exo | $35M | 05 Aug 2019 | Redwood City, California, United States |
– Vedanta Biosciences, Inc. from Cambridge, MA develops new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks.
– The company closed a $68m Series D financing.
– The round was led by affiliates of Magnetar Capital with participation from Verition Fund Management, Fosun Health Capital, co-founder PureTech Health (Nasdaq: PRTC, LSE: PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corporation, SymBiosis LLC, Shumway Capital, Health for Life Capital (Seventure Partners), and other institutional investors.
– The company plans to use the funds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrentCDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
CoreWeave | $200M | 31 May 2023 | New York, New York, United States | ||
CoreWeave | $221M | 20 Apr 2023 | New York, New York, United States | ||
Enable Injections | $215M | 27 Jan 2022 | Cincinnati, Ohio, United States | ||
ViRB | $3M | 02 Jan 2022 | Brookline, Massachusetts, United States | ||
Activ Surgical | $45M | 02 Jul 2021 | Boston, Massachusetts, United States | ||
OncoResponse | $40M | 31 Mar 2021 | Seattle, Washington, United States | ||
Imvax | $112M | 16 Jul 2020 | Philadelphia, Pennsylvania, United States | ||
Imvax | $40M | 10 Sep 2019 | Philadelphia, Pennsylvania, United States | ||
Exo | $35M | 05 Aug 2019 | Redwood City, California, United States |
